CRIS

Permanent URI for this communityhttps://investigadores.udd.cl/handle/123456789/1

Browse

Search Results

Now showing 1 - 6 of 6
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Carbapenem-resistant Enterobacterales in solid organ transplant recipients
    (2024)
    Angelique E. Boutzoukas
    ;
    Weixiao Dai
    ;
    Eric Cober
    ;
    Lilian M. Abbo
    ;
    Lauren Komarow
      1
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in
    <i>Pseudomonas aeruginosa</i>
    of clinical origin
    (2024)
    Stephanie L. Egge
    ;
    Samie A. Rizvi
    ;
    Shelby R. Simar
    ;
    ;
    JOSE RODRIGO WALDEMAR MARTINEZ SOLIS
    <jats:title>ABSTRACT</jats:title> <jats:sec> <jats:title/> <jats:p> The siderophore-cephalosporin cefiderocol (FDC) presents a promising treatment option for carbapenem-resistant (CR) <jats:italic>P. aeruginosa</jats:italic> (PA). FDC circumvents traditional porin and efflux-mediated resistance by utilizing TonB-dependent receptors (TBDRs) to access the periplasmic space. Emerging FDC resistance has been associated with loss of function mutations within TBDR genes or the regulatory genes controlling TBDR expression. Further, difficulties with antimicrobial susceptibility testing (AST) and unexpected negative clinical treatment outcomes have prompted concerns for heteroresistance, where a single lineage isolate contains resistant subpopulations not detectable by standard AST. This study aimed to evaluate the prevalence of TBDR mutations among clinical isolates of <jats:italic>P. aeruginosa</jats:italic> and the phenotypic effect on FDC susceptibility and heteroresistance. We evaluated the sequence of <jats:italic>pirR</jats:italic> , <jats:italic>pirS</jats:italic> , <jats:italic>pirA</jats:italic> , <jats:italic>piuA</jats:italic> , or <jats:italic>piuD</jats:italic> from 498 unique isolates collected before the introduction of FDC from four clinical sites in Portland, OR (1), Houston, TX (2), and Santiago, Chile (1). At some clinical sites, TBDR mutations were seen in up to 25% of isolates, and insertion, deletion, or frameshift mutations were predicted to impair protein function were seen in 3% of all isolates ( <jats:italic>n</jats:italic> = 15). Using population analysis profile testing, we found that <jats:italic>P. aeruginosa</jats:italic> with major TBDR mutations were enriched for a heteroresistant phenotype and undergo a shift in the susceptibility distribution of the population as compared to susceptible strains with wild-type TBDR genes. Our results indicate that mutations in TBDR genes predate the clinical introduction of FDC, and these mutations may predispose to the emergence of FDC resistance. </jats:p> </jats:sec>
    Scopus© Citations 18  2
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Multisite Detection of Tn
    <i>1549</i>
    -Mediated
    <i>vanB</i>
    Vancomycin Resistance in Multidrug-Resistant Enterococcus faecalis ST6 in Texas and Florida
    (2023)
    Shelby R. Simar
    ;
    Truc T. Tran
    ;
    Kirsten B. Rydell
    ;
    Diana Panesso
    ;
    German A. Contreras
    <jats:p> In the United States, <jats:italic>vanB</jats:italic> -mediated resistance in enterococci is rare. We characterized three sequence type (ST) 6, vancomycin-resistant <jats:named-content content-type="genus-species">Enterococcus faecalis</jats:named-content> isolates causing bacteremia in unique patients in spatiotemporally distinct settings. </jats:p>
      7  1Scopus© Citations 3
  • Some of the metrics are blocked by your 
    Item type:Publication,
      4
  • Some of the metrics are blocked by your 
    Item type:Publication,
    <i>In Vivo</i> Resistance to Ceftolozane/Tazobactam in <i>Pseudomonas aeruginosa</i> Arising by AmpC- and Non-AmpC-Mediated Pathways
    (2018)
    Erik Skoglund
    ;
    Henrietta Abodakpi
    ;
    Rafael Rios
    ;
    Lorena Diaz
    ;
    Elsa De La Cadena
    <jats:p>Two pairs of ceftolozane/tazobactam susceptible/resistant <jats:italic>P. aeruginosa</jats:italic> were isolated from 2 patients after exposure to <jats:italic>β</jats:italic>-lactams. The genetic basis of ceftolozane/tazobactam resistance was evaluated, and <jats:italic>β</jats:italic>-lactam-resistant mechanisms were assessed by phenotypic assays. Whole genome sequencing identified mutations in AmpC including the mutation (V213A) and a deletion of 7 amino acids (P210–G216) in the Ω-loop. Phenotypic assays showed that ceftolozane/tazobactam resistance in the strain with AmpC<jats:sub>V213A</jats:sub> variant was associated with increased <jats:italic>β</jats:italic>-lactamase hydrolysis activity. On the other hand, the deletion of 7 amino acids in the Ω-loop of AmpC did not display enhanced <jats:italic>β</jats:italic>-lactamase activity. Resistance to ceftolozane/tazobactam in <jats:italic>P. aeruginosa</jats:italic> is associated with changes in AmpC; however, the apparent loss of <jats:italic>β</jats:italic>-lactamase activity in AmpC∆7 suggests that non-AmpC mechanisms could play an important role in resistance to <jats:italic>β</jats:italic>-lactam/<jats:italic>β</jats:italic>-lactamase inhibitor combinations.</jats:p>
      4
  • Some of the metrics are blocked by your 
    Item type:Publication,
    Influence of Inoculum Effect on the Efficacy of Daptomycin Monotherapy and in Combination with beta-Lactams against Daptomycin-Susceptible Enterococcus faecium Harboring LiaSR Substitutions
    (2018)
    Razieh Kebriaei
    ;
    Seth A. Rice
    ;
    Kavindra V. Singh
    ;
    Kyle C. Stamper
    ;
    An Q. Dinh
    <jats:p> <jats:named-content content-type="genus-species">Enterococcus faecium</jats:named-content> isolates that harbor LiaFSR substitutions but are phenotypically susceptible to daptomycin (DAP) by current breakpoints are problematic, since predisposition to resistance may lead to therapeutic failure. Using a simulated endocardial vegetation (SEV) pharmacokinetic/pharmacodynamic (PK/PD) model, we investigated DAP regimens (6, 8, and 10 mg/kg of body weight/day) as monotherapy and in combination with ampicillin (AMP), ceftaroline (CPT), or ertapenem (ERT) against <jats:named-content content-type="genus-species">E. faecium</jats:named-content> HOU503, a DAP-susceptible strain that harbors common LiaS and LiaR substitutions found in clinical isolates (T120S and W73C, respectively). </jats:p>
      3  1Scopus© Citations 37